← Eichor
Condition: Transarterial Chemoembolization Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Transarterial Chemoembolization

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage Hepato
Phase 3 · 72 location(s) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhau · NCT04803994Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT
Phase 2 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT06904183Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relap
Phase N/A · 1 location(s) · Ting YANG · NCT07198230A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination Wi
Phase 2 · 2 location(s) · TaiRx, Inc. · NCT07521852Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk R
Phase 2 · 4 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07239245Effects of Antrodia Cinnamomea on the Hepatoma Patients After Transcatheter Hepatic Artery Chemoembolization
NA · 1 location(s) · Taichung Tzu Chi Hospital · NCT07178093A Study of PTX-9908 Injection for Non-resectable HCC with TACE
Phase 1/Phase 2 · 1 location(s) · TCM Biotech International Corp. · NCT03812874Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)
Phase 2/Phase 3 · 1 location(s) · Tuen Mun Hospital · NCT07293468Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT
Phase 3 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT06492395TACE Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients with Hepatocellular Carcinoma
Phase 2 · 1 location(s) · Seoul National University Hospital · NCT06114082A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepato
Phase N/A · 1 location(s) · Zhongda Hospital · NCT07351669A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Ca
Phase 2/Phase 3 · 2 location(s) · Zhejiang Raygene Pharmaceuticals Co., Ltd · NCT06844357Adjuvant TACE in HCC With High-risk Recurrence Factors
Phase 3 · 1 location(s) · Guangxi Medical University · NCT07417397Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma
Phase 2 · 1 location(s) · University of California, Irvine · NCT04472767A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With
Phase 3 · 4 location(s) · Akeso · NCT06371157Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma
Phase 1/Phase 2 · 1 location(s) · Yoon Jun Kim · NCT06911255Prognosis Stratification for Advanced HCC Receiving TACE with PD-1/PD-L1 Inhibitors and Molecular Target Therapies
Phase N/A · 1 location(s) · Zhongda Hospital · NCT06607120TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma
Phase 2 · 2 location(s) · The University of Hong Kong · NCT04988945A Study of Standard Of Care Versus Radio Ablation in Early Stage HCC
NA · 2 location(s) · University Health Network, Toronto · NCT07628751Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC
Phase 3 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07186621Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT05751343Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC
Phase 3 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT05608200To Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization
Phase 1/Phase 2 · 2 location(s) · Febico Biomedical Corp. · NCT06478719Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma
Phase 2/Phase 3 · 3 location(s) · University Hospital, Basel, Switzerland · NCT07302919Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma
Phase 3 · 1 location(s) · London Health Sciences Centre Research Institute OR Lawson R · NCT03895359HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven)
Phase 3 · 1 location(s) · Binkui Li · NCT07594340Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases
Phase 1/Phase 2 · 1 location(s) · Pardis Noor Medical Imaging and Cancer Center · NCT06311851DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
Phase 2 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT06397235Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT06788353TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma
Phase 3 · 1 location(s) · Guohui Xu · NCT06485466
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.